Nurix Therapeutics is trading 4.1% up at $24.18 on solid intraday gains, appearing to track a broader risk-on rally as major U.S. indices climb more than 1%.
- The move suggests investors are adding exposure to higher-beta biotech names alongside overall market strength.
- No fresh company-specific news, regulatory filings, or specific catalysts have been identified to account for the move.